Quarterly Metrics: Quick and Current Ratios for Lyra Therapeutics Inc (LYRA)

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Lyra Therapeutics Inc’s stock clocked out at $0.27, up 10.07% from its previous closing price of $0.24. In other words, the price has increased by $10.07 from its previous closing price. On the day, 1.07 million shares were traded. LYRA stock price reached its highest trading level at $0.2683 during the session, while it also had its lowest trading level at $0.25.

Ratios:

To gain a deeper understanding of LYRA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.60. In the meantime, Its Debt-to-Equity ratio is 1.19 whereas as Long-Term Debt/Eq ratio is at 1.05.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on May 07, 2024, Downgraded its rating to Hold and sets its target price to $0.50 from $10 previously.

On May 07, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $12 to $2.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 10 ’23 when Waksal Harlan bought 25,000 shares for $2.96 per share. The transaction valued at 74,095 led to the insider holds 261,966 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYRA now has a Market Capitalization of 17391846 and an Enterprise Value of -13358146. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.56 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at -7.34 whereas that against EBITDA is 0.18.

Stock Price History:

Over the past 52 weeks, LYRA has reached a high of $6.79, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -10.31%, while the 200-Day Moving Average is calculated to be -90.35%.

Shares Statistics:

It appears that LYRA traded 1.12M shares on average per day over the past three months and 571980 shares per day over the past ten days. A total of 57.21M shares are outstanding, with a floating share count of 56.40M. Insiders hold about 13.84% of the company’s shares, while institutions hold 45.86% stake in the company. Shares short for LYRA as of 1726185600 were 3138882 with a Short Ratio of 2.80, compared to 1723680000 on 4151198. Therefore, it implies a Short% of Shares Outstanding of 3138882 and a Short% of Float of 5.9799999999999995.

Most Popular